FOLD Amicus Pharma Return on Sales by Gross Profit

Amicus Therapeutics specializes in the therapy of rare metabolic pathologies, focusing on genetic engineering. Its monopoly status and the life-critical nature of its drugs guarantee premium pricing. The gross margin value confirms this efficiency, with the metric standing at 87.30. However, high development costs and pressure from global pharma behemoths create serious risks for the company's long-term dominance.
Financial and market metric breakdowns for amicusrx.com (FOLD)

The specialization of Amicus Therapeutics (FOLD) in rare disease therapy and the commercialization of Galafold drive high R&D costs, making the gross margin a key metric for assessing how effectively revenue covers direct expenses. Analyzing the average gross margin reveals the gap between operating profitability and market price, where inflated figures signal an overbought asset, while a decline warns of deteriorating fundamental value.